- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07943312
GA001 Injection in Retinitis Pigmentosa
A Clinical Study to Evaluate the Safety and Efficacy of GA001 Injection in Patients With Retinitis Pigmentosa
This Phase II clinical trial evaluates the safety, tolerability, and efficacy of GA001 Injection in patients with retinitis pigmentosa.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Retinitis pigmentosa (RP) is an inherited retinal disease that causes gradual vision loss and can lead to blindness, with no approved curative treatment currently available.
This Phase II study is designed to evaluate the safety, tolerability, and efficacy of a single unilateral intravitreal injection of GA001 Injection at the target dose compared with sham injection in patients with retinitis pigmentosa. The study employs a sham-controlled design and will assess safety and efficacy outcomes as well as multiple functional and structural measures of visual performance over long-term follow-up.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
- Nome: Xiaodong Sun Principal Investigator, PhD
- Número de telefone: 86 17853138155
- E-mail: xdsun@sjtu.edu.cn
Locais de estudo
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200080
- Shanghai General Hospital
-
Contato:
- Xiaodong Sun
- Número de telefone: 86-1566269037
- E-mail: guanranzhang@126.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Male or female participants aged 18 to 70 years.
- Clinical diagnosis of advanced retinitis pigmentosa (RP).
- Best corrected visual acuity at or below the protocol-defined threshold in the study eye.
- Ability to understand and sign informed consent (and assent, when applicable).
- Laboratory test results are within the protocol-defined threshold range.
Exclusion Criteria:
- Presence of other ocular conditions that could interfere with study assessments.
- History of significant ocular surgery in the study eye within a protocol-defined period.
- Active ocular infection or inflammation.
- Clinically significant systemic disease that could increase study risk or interfere with assessments.
- Positive screening for clinically significant infectious diseases, as defined in the protocol.
- Any condition that, in the investigator's judgment, would make the participant unsuitable for study participation.
- Pregnant or breastfeeding individuals.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição cruzada
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: GA001
|
Single unilateral IVT injection of GA001 Injection in the study eye |
|
Comparador Falso: Sham Injection
|
Sham IVT procedure in the study eye |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
To evaluate the efficacy of GA001 Injection in patients with retinitis pigmentosa
Prazo: Baseline to Week 52
|
BCVA-Change from Baseline in LogMAR Best Corrected Visual Acuity (BCVA) BCVA assessed by ETDRS charts at each post-treatment visit compared with the sham group.baseline→W52,Unit: LogMAR MLMT-Change from Baseline in Multi-Luminance Mobility Test (MLMT) Performance MLMT 7 levels; baseline→W52 ambient Lux to finish course, vs. sham. Unit: Lux Light Sensitivity-Change from Baseline in Light Sensitivity (Minimum Identifiable Brightness) Min brightness (Lux), study eye; baseline→W52, vs. sham. Unit: Lux FST Threshold-Change from Baseline in Full-Field Stimulus Test (FST) Threshold Full-field stimulus test; baseline→W52, vs. sham. Unit: log cd·s/m² Central Visual Field-Change from Baseline in Central Visual Field Static perimetry; baseline→W52, vs. sham. Unit: dB (mean deviation) MRDQ-Change from Baseline in Michigan Retinal Degeneration Questionnaire (MRDQ) Total Score MRDQ total score; baseline→W52, vs. sham. Unit: total score (points) |
Baseline to Week 52
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Incidence of Treatment-Emergent Adverse Events and serious adverse events
Prazo: Baseline to Week 52
|
Incidence of severity of ocular and systemic adverse events (AEs) and serious adverse events (SAEs) following a single intravitreal injection of GA001 |
Baseline to Week 52
|
|
Evaluation of the Immunogenicity of GA001 Injection after a Single Intravitreal Administration in Patients with Retinitis Pigmentosa
Prazo: Baseline to Week 52
|
Immunogenicity of GA001 Injection will be evaluated following a single intravitreal injection in patients with retinitis pigmentosa, by AAV neutralizing antibody titers in peripheral blood (cell-based neutralizing assay) and by analysis of GA001-specific T-cell immune responses. |
Baseline to Week 52
|
|
Maximum Concentration (Cmax) of GA001 Vector DNA
Prazo: Baseline to Week 52
|
Cmax of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa. |
Baseline to Week 52
|
|
Area Under the Concentration-Time Curve (AUC) of GA001 Vector DNA
Prazo: Baseline to Week 52
|
AUC of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa. |
Baseline to Week 52
|
|
Time to Maximum Concentration (Tmax) of GA001 Vector DNA
Prazo: Baseline to Week 52
|
Tmax of GA001 vector DNA will be determined by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa. |
Baseline to Week 52
|
|
Biodistribution of GA001 Vector DNA
Prazo: Baseline to Week 52
|
Biodistribution of GA001 vector DNA will be assessed by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa. |
Baseline to Week 52
|
|
Shedding of GA001 Vector DNA
Prazo: Baseline to Week 52
|
Shedding of GA001 vector DNA will be assessed by PCR at prespecified timepoints after a single intravitreal administration in patients with retinitis pigmentosa. |
Baseline to Week 52
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- GA001-2025
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .